Literature DB >> 17952387

Clinical implications of discordant viral and immune outcomes following protease inhibitor containing antiretroviral therapy for HIV-infected children.

Carina A Rodriguez1, Sarah Koch, Maureen Goodenow, John W Sleasman.   

Abstract

Many HIV-infected children treated with protease inhibitors (PI) reconstitute immunity despite viral breakthrough predicting disease progression. We studied a unique cohort of PI treated children with advanced disease who demonstrated sustained CD4 T cell counts but median post therapy viral load rebounded to >4.0 log(10) copies/ml. Phylogenetic relationships between pre- and post-therapy viruses reveals significant bottlenecks for quasispecies with natural polymorphisms mapping outside of protease active site providing selective advantage for emergence. Among discordant subjects post-therapy viruses fell into two phenotypes; high viral loads (median >5.0 log(10) copies/ml) and attenuated post-therapy replication (median <4.0 log(10) copies/ml). Both groups showed similar degrees of CD4 T cell immune reconstitution and were similar to children who optimally suppressed virus to <400 copies/ml. Both high fit and low fit discordant response groups showed high reconstitution of naïve CD4 CD45RA T cells (median 388 and 357 cells/microl, respectively). Naïve T cells increases suggest virus replicating under PI selective pressure do not impair thymic output. If therapeutic options are limited, selection of therapy which allows immune reconstitution despite suboptimal viral control may be beneficial. This novel paradigm for virus/host interactions may lead to therapeutic approaches to attenuate viral pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17952387     DOI: 10.1007/s12026-007-0031-1

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  82 in total

Review 1.  Cellular immune responses to HIV.

Authors:  A J McMichael; S L Rowland-Jones
Journal:  Nature       Date:  2001-04-19       Impact factor: 49.962

2.  Persistence of drug-resistant HIV-1 after a structured treatment interruption and its impact on treatment response.

Authors:  Steven G Deeks; Robert M Grant; Terri Wrin; Ellen E Paxinos; Teri Liegler; Rebecca Hoh; Jeff N Martin; Christos J Petropoulos
Journal:  AIDS       Date:  2003-02-14       Impact factor: 4.177

3.  Guidelines for the use of antiretroviral agents in pediatric HIV infection. Center for Disease Control and Prevention.

Authors: 
Journal:  MMWR Recomm Rep       Date:  1998-04-17

4.  Predictors of long-term increase in CD4(+) cell counts in human immunodeficiency virus-infected patients receiving a protease inhibitor-containing antiretroviral regimen.

Authors:  Vincent Le Moing; Rodolphe Thiébaut; Geneviève Chêne; Catherine Leport; Valérie Cailleton; Christian Michelet; Hervé Fleury; Serge Herson; François Raffi
Journal:  J Infect Dis       Date:  2002-01-31       Impact factor: 5.226

Review 5.  Dressed to kill? A review of why antiviral CD8 T lymphocytes fail to prevent progressive immunodeficiency in HIV-1 infection.

Authors:  J Lieberman; P Shankar; N Manjunath; J Andersson
Journal:  Blood       Date:  2001-09-15       Impact factor: 22.113

6.  In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors.

Authors:  J H Condra; W A Schleif; O M Blahy; L J Gabryelski; D J Graham; J C Quintero; A Rhodes; H L Robbins; E Roth; M Shivaprakash
Journal:  Nature       Date:  1995-04-06       Impact factor: 49.962

7.  Decreased levels of recent thymic emigrants in peripheral blood of simian immunodeficiency virus-infected macaques correlate with alterations within the thymus.

Authors:  Donald L Sodora; Jeffrey M Milush; Felecia Ware; Aneta Wozniakowski; Lisa Montgomery; Harold M McClure; Andrew A Lackner; Marta Marthas; Vanessa Hirsch; R Paul Johnson; Daniel C Douek; Richard A Koup
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

8.  Distinctive effects of CCR5, CCR2, and SDF1 genetic polymorphisms in AIDS progression.

Authors:  H Hendel; N Hénon; H Lebuanec; A Lachgar; H Poncelet; S Caillat-Zucman; C A Winkler; M W Smith; L Kenefic; S O'Brien; W Lu; J M Andrieu; D Zagury; F Schächter; J Rappaport; J F Zagury
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1998-12-01

9.  Changes in thymic function with age and during the treatment of HIV infection.

Authors:  D C Douek; R D McFarland; P H Keiser; E A Gage; J M Massey; B F Haynes; M A Polis; A T Haase; M B Feinberg; J L Sullivan; B D Jamieson; J A Zack; L J Picker; R A Koup
Journal:  Nature       Date:  1998-12-17       Impact factor: 49.962

10.  Influence of the CCR2-V64I polymorphism on human immunodeficiency virus type 1 coreceptor activity and on chemokine receptor function of CCR2b, CCR3, CCR5, and CXCR4.

Authors:  B Lee; B J Doranz; S Rana; Y Yi; M Mellado; J M Frade; C Martinez-A; S J O'Brien; M Dean; R G Collman; R W Doms
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103

View more
  5 in total

1.  Developmental regulation of P-glycoprotein activity within thymocytes results in increased anti-HIV protease inhibitor activity.

Authors:  Soichi Haraguchi; Sarah K Ho; Matthew Morrow; Maureen M Goodenow; John W Sleasman
Journal:  J Leukoc Biol       Date:  2011-04-19       Impact factor: 4.962

2.  Incomplete immune reconstitution despite virologic suppression in HIV-1 infected children and adolescents.

Authors:  Paul Krogstad; Kunjal Patel; Brad Karalius; Rohan Hazra; Mark J Abzug; James Oleske; George R Seage; Paige L Williams; William Borkowsky; Andrew Wiznia; Jorge Pinto; Russell B Van Dyke
Journal:  AIDS       Date:  2015-03-27       Impact factor: 4.177

3.  It is time to consider third-line options in antiretroviral-experienced paediatric patients?

Authors:  Gert U van Zyl; Helena Rabie; James J Nuttall; Mark F Cotton
Journal:  J Int AIDS Soc       Date:  2011-11-15       Impact factor: 5.396

4.  Microbial translocation induces persistent macrophage activation unrelated to HIV-1 levels or T-cell activation following therapy.

Authors:  Mark A Wallet; Carina A Rodriguez; Li Yin; Sara Saporta; Sasawan Chinratanapisit; Wei Hou; John W Sleasman; Maureen M Goodenow
Journal:  AIDS       Date:  2010-06-01       Impact factor: 4.177

5.  Genetic determinants in HIV-1 Gag and Env V3 are related to viral response to combination antiretroviral therapy with a protease inhibitor.

Authors:  Sarah K Ho; Elena E Perez; Stephanie L Rose; Roxana M Coman; Amanda C Lowe; Wei Hou; Changxing Ma; Robert M Lawrence; Ben M Dunn; John W Sleasman; Maureen M Goodenow
Journal:  AIDS       Date:  2009-08-24       Impact factor: 4.177

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.